Bioavailability and Bioequivalence Study of Two Different Sources of Opicapone

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
The purpose of this study is to evaluate the bioavailability and the bioequivalence between two active pharmaceutical ingredient (API) sources of opicapone (OPC) at two different dosage strengths (25 mg and 50 mg) after a single oral dose administration under fasting conditions in healthy male and female subjects.
Epistemonikos ID: 2b642481a332f70ab3ae1b99a41fd4eac8919fee
First added on: May 20, 2024